-

06:23:33 AM

ALVR Stock News

ALVR - AlloVir Inc

05/05/22 7:00 AM

Nasdaq : ALVR

earnings

AlloVir Reports First Quarter 2022 Financial Results

AlloVir, Inc., a multiple Phase 3 clinical trial stage allogeneic T cell immunotherapy company, today reported financial results for the first quarter ended March 31, 2022. Based on the strength of our Phase 2 data in both treatment and prevention, we now have three Phase 3 studies underway that aim to address a spectrum of needs in the post-allo-HCT setting– as a...

RHEA-AI

neutral

04/20/22 7:00 AM

Nasdaq : ALVR

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to its lead investigational multi-virus-specific T cell therapy, posoleucel, for the prevention of clinically significant infections and disease from six...

RHEA-AI

neutral

03/31/22 7:00 AM

Nasdaq : ALVR

management

AlloVir Appoints Shawn Tomasello to Its Board of Directors

AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Her depth of experience in building successful biopharmaceutical companies and leading innovative cell and gene therapies from clinical development to commercialization is invaluable to AlloVir, as we...

RHEA-AI

neutral

03/22/22 7:00 AM

Nasdaq : ALVR

clinical trial

AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced the initiation of a Phase 3 registrational study of posoleucel, an allogeneic, off-the-shelf, multi-virus-specific T-cell therapy, for the prevention of clinically significant infections and end-organ diseases from six potentially life-threatening viruses–...

RHEA-AI

negative

02/11/22 7:00 AM

Nasdaq : ALVR

conferences

AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

AlloVir, a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:00 a.m. EST. A live webcast of the fireside chat will be available on the Investors& Press section...

RHEA-AI

neutral

02/10/22 7:00 AM

Nasdaq : ALVR

earnings

AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook

AlloVir, a late clinical-stage allogeneic T cell immunotherapy company, today reported full-year 2021 financial results for the period ended December 31, 2021. “2022 is a year of execution and expansion for our clinical development program, as we implement three Phase 3 registrational studies across sites in North America, Europe and Asia, present new data...

RHEA-AI

neutral

01/05/22 7:30 AM

Nasdaq : ALVR

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation

AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced that the U.S. Food and Drug Administration has granted its lead multi-virus specific T cell therapy, posoleucel, Regenerative Medicine Advanced Therapy designation for the treatment of adenovirus infection following allogeneic hematopoietic stem cell...

RHEA-AI

very positive

01/03/22 4:05 PM

Nasdaq : ALVR

conferences

AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference

AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30 p.m. ET. An audio-only webcast of the presentation will be available on the Investors& Press section of the AlloVir...

RHEA-AI

neutral

12/16/21 4:05 PM

Nasdaq : ALVR

AlloVir Announces Departure of Chief Medical Officer Augustin Melian

Although officially leaving the company, Dr. Melian has agreed to work with AlloVir in an advisory capacity to ensure a smooth transition. I’ m very grateful for his contributions, which have helped establish AlloVir as a leader in this field and position us well for our next stage of growth,” said Diana Brainard, MD, Chief Executive Officer, AlloVir.

RHEA-AI

neutral

12/11/21 1:00 PM

Nasdaq : ALVR

clinical trial

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary data from the ongoing open-label portion of a Phase 2 study assessing the safety and efficacy of posoleucel for the prevention of clinically significant infections and end-organ diseases from six potentially life-threatening viruses in high-risk...

RHEA-AI

neutral

ALVR Data

IndustryResearch and Development in Biotechnology
Websitewww.allovir.com
Security nameAlloVir Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2836
Employees53
Tags
- Health Technology
- Biotechnology

About AlloVir Inc

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.